Eleison Pharmaceuticals (ELSN) Files IPO Registration Statement

Eleison Pharmaceuticals (NASDAQ: ELSN) has filed for a proposed Nasdaq IPO.

The company describes itself as: "We are a clinical stage biopharmaceutical company dedicated to acquiring, developing and commercializing late-stage therapies (in Phase II or Phase III trials) to treat rare, life-threatening diseases, such as pancreatic cancer, small cell lung cancer, pediatric bone cancer and brain cancer. We were formed in 2009 by Edwin J. Thomas, our chief executive officer and chairman, who through his extensive prior experience as a C-suite executive in several biopharmaceutical companies saw first-hand the need and commercial opportunity for therapies for rare, life threatening diseases with unmet needs."

ThinkEquity will serve as sole underwriter.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Wolfspeed (WOLF) Comments on Letter from JANA Partners
• Adobe Systems (ADBE) Introduces Firefly Image 3 Foundation Model